Sanara MedTech (SMTI) Expected to Announce Quarterly Earnings on Monday

Sanara MedTech (NASDAQ:SMTI) is anticipated to announce its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $22.75 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Sanara MedTech Price Performance

Shares of SMTI opened at $33.60 on Friday. The company has a market capitalization of $293.70 million, a P/E ratio of -33.94 and a beta of 1.37. Sanara MedTech has a twelve month low of $26.00 and a twelve month high of $39.08. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76. The firm has a 50 day moving average of $34.36 and a 200 day moving average of $33.84.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Sanara MedTech in a report on Thursday, January 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $44.00 target price on shares of Sanara MedTech in a research report on Wednesday, January 22nd.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.